These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38308624)

  • 1. A primer on formulary structures and strategies.
    Hydery T; Reddy V
    J Manag Care Spec Pharm; 2024 Feb; 30(2):206-210. PubMed ID: 38308624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulary management in the Department of Defense.
    Trice S; Devine J; Mistry H; Moore E; Linton A
    J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of pharmacoeconomics to formulary management in a health system setting.
    Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
    Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee.
    Leonard MC; Thyagarajan R; Wilson AJ; Sekeres MA
    Am J Health Syst Pharm; 2018 Apr; 75(7):451-455. PubMed ID: 29572313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The formulary process for biosimilar additions at a comprehensive cancer center.
    Aschermann LM; Forshay CM; Kennerly-Shah J; Pilz J
    J Oncol Pharm Pract; 2022 Jan; 28(1):185-189. PubMed ID: 34565230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacy formularies in integrated health systems.
    Osborne JA
    J Healthc Resour Manag; 1997; 15(1):18-20. PubMed ID: 10164678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development.
    Friesen P; Caplan AL; Miller JE
    J Clin Pharm Ther; 2020 Apr; 45(2):249-255. PubMed ID: 31657022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar Products in the Modern U.S. Health Care and Regulatory Landscape.
    Peterson J; Budlong H; Affeldt T; Skiermont K; Kyllo G; Heaton A
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1255-1259. PubMed ID: 29172981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The formulary decision-making process in a health maintenance organisation setting.
    Shepherd MD; Salzman RD
    Pharmacoeconomics; 1994 Jan; 5(1):29-38. PubMed ID: 10146864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
    Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
    J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
    Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
    J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMCP Partnership Forum: Optimizing Prior Authorization for Appropriate Medication Selection.
    J Manag Care Spec Pharm; 2020 Jan; 26(1):55-62. PubMed ID: 31880226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription drug formularies in managed care: concerns for the elderly population.
    Gross DJ
    Clin Ther; 1998; 20(6):1277-91. PubMed ID: 9916619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar strategic implementation at a large health system.
    Kar I; Kronz M; Kolychev E; Silverman P; Mendiratta P; Tomlinson BKN; Prunty J; Copley M; Patel S; Caudill S; Farah L; Wesolowski B; Crissinger T; Kendig C; Szymczak E; Duraj L; Dumot J; Acheson E; Lyamkin S; King M; Mocilnikar A; Cunningham K; Paulic N; Botzki U; Lerman R; Strosaker R; Osborne S; Glotzbecker B
    Am J Health Syst Pharm; 2022 Feb; 79(4):268-275. PubMed ID: 34752608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specialty pharmacy turnaround time impediments, facilitators, and good practices.
    Gabriel MH; Kotschevar CM; Tarver D; Mastrangelo V; Pezzullo L; Campbell PJ
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1244-1251. PubMed ID: 36282928
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacist biosimilar survey reveals knowledge gaps.
    Stevenson JG; McCabe D; McGrath M; McBride A
    J Am Pharm Assoc (2003); 2023; 63(2):529-537.e7. PubMed ID: 36437154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Framework for Integrating Biosimilars Into the Didactic Core Requirements of a Doctor of Pharmacy Curriculum.
    Li E; Liu J; Ramchandani M
    Am J Pharm Educ; 2017 Apr; 81(3):57. PubMed ID: 28496277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.